MARKET

INSM

INSM

Insmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.54
-0.55
-2.19%
After Hours: 24.54 0 0.00% 16:09 07/29 EDT
OPEN
25.24
PREV CLOSE
25.09
HIGH
25.39
LOW
24.46
VOLUME
636.15K
TURNOVER
--
52 WEEK HIGH
45.44
52 WEEK LOW
23.28
MARKET CAP
2.78B
P/E (TTM)
-7.7786
1D
5D
1M
3M
1Y
5Y
Earnings Preview: Insmed (INSM) Q2 Earnings Expected to Decline
Zacks.com · 12h ago
Here's Why Insmed (INSM) is Poised for a Turnaround After Losing 19.5% in 4 Weeks
Zacks.com · 2d ago
Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2021 financial results on .
PR Newswire - PRF · 2d ago
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 2d ago
Stocks That Hit 52-Week Lows On Monday
    Monday morning saw 115 companies set new 52-week lows.
Benzinga · 3d ago
Where Do Hedge Funds Stand On Insmed Incorporated (INSM)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and no...
Insider Monkey · 07/19 16:08
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 12 new employees. In accordance with ...
PR Newswire - PRF · 07/08 12:00
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
Benzinga · 06/27 16:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INSM. Analyze the recent business situations of Insmed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INSM stock price target is 53.33 with a high estimate of 60.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 296
Institutional Holdings: 121.42M
% Owned: 107.19%
Shares Outstanding: 113.28M
TypeInstitutionsShares
Increased
66
10.61M
New
20
951.15K
Decreased
82
11.01M
Sold Out
28
800.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/President/Chief Executive Officer/Director
William Lewis
Chief Financial Officer
Sara Bonstein
Chief Operating Officer
Roger Adsett
Senior Vice President/General Counsel
Michael Smith
Chief Compliance Officer
John Soriano
Other
Martina Flammer
Other
S. Nicole Schaeffer
Lead Director/Independent Director
David Brennan
Independent Director
Alfred Altomari
Independent Director
Elizabeth Anderson
Independent Director
Clarissa Desjardins
Independent Director
Steinar Engelsen
Independent Director
Leo Lee
Independent Director
David McGirr
Independent Director
Carol Schafer
Independent Director
Melvin Sharoky
No Data
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Webull offers kinds of Insmed Incorporated stock information, including NASDAQ:INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.